- Home
- CTS vs AUPH Comparison
CTS vs AUPH Comparison
Compare CTS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTS
- AUPH
- Stock Information
- Founded
- CTS 1896
- AUPH 1993
- Country
- CTS United States
- AUPH Canada
- Employees
- CTS N/A
- AUPH N/A
- Industry
- CTS Electrical Products
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CTS Technology
- AUPH Health Care
- Exchange
- CTS Nasdaq
- AUPH Nasdaq
- Market Cap
- CTS 1.1B
- AUPH 999.8M
- IPO Year
- CTS N/A
- AUPH 1999
- Fundamental
- Price
- CTS $39.88
- AUPH $8.00
- Analyst Decision
- CTS
- AUPH Strong Buy
- Analyst Count
- CTS 0
- AUPH 2
- Target Price
- CTS N/A
- AUPH $11.50
- AVG Volume (30 Days)
- CTS 186.7K
- AUPH 971.5K
- Earning Date
- CTS 04-30-2025
- AUPH 05-12-2025
- Dividend Yield
- CTS 0.40%
- AUPH N/A
- EPS Growth
- CTS 16.02
- AUPH N/A
- EPS
- CTS 1.97
- AUPH 0.04
- Revenue
- CTS $515,789,999.00
- AUPH $235,133,000.00
- Revenue This Year
- CTS $4.41
- AUPH $11.86
- Revenue Next Year
- CTS $7.00
- AUPH $24.96
- P/E Ratio
- CTS $20.28
- AUPH $199.38
- Revenue Growth
- CTS N/A
- AUPH 33.97
- 52 Week Low
- CTS $34.02
- AUPH $4.98
- 52 Week High
- CTS $59.68
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CTS 52.35
- AUPH 48.76
- Support Level
- CTS $38.12
- AUPH $7.89
- Resistance Level
- CTS $40.51
- AUPH $8.38
- Average True Range (ATR)
- CTS 1.14
- AUPH 0.24
- MACD
- CTS 0.31
- AUPH 0.01
- Stochastic Oscillator
- CTS 78.28
- AUPH 39.68
About CTS CTS Corporation
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.